4
Changes in Ownership
Trevi Therapeutics, Inc. Filed Acc 0001209191-23-037029
Chief Financial Officer sold 610 shares at $2.64 ($1,610)
- Chief Financial Officer acquired 2,291 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Delfini Lisa · Chief Financial Officer
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-06-12 | Exercise or conversion : show line 1 in the form 10b5-1 | +2,291 | $0.51 | $1,171 | 30,209 | D |
| 2023-06-12 | Sale : show line 2 in the form 10b5-1 | −610 | $2.64 | $1,610 | 29,599 | D |
| Open-market sales · 610 sh · avg $2.64 · $1,610 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2023-06-12 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option (right to buy) | −2,291 | 73,335 | D |
Loading xslF345X04/doc4.xml…